Drug Pipeline

DS-1001b Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
1
Phase 3
3
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT05303519
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)		 Trial sites expanded: 45 -> 55 locations
Active Studies by Phase
Phase 3
1
Phase 2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05303519 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Glioma Recruiting
Phase 2
NCT04458272 A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated… WHO Grade II Glioma Active, Not Recruiting
Phase 1
NCT03030066 Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas Glioma Active, Not Recruiting
Sponsors Running DS-1001b Trials
Daiichi Sankyo (1) Daiichi Sankyo Co., Ltd. (1) Nuvation Bio Inc. (1)
Disease Areas
Glioma (3)
Get alerts when DS-1001b trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free